Background/Aims: The purpose of this study was to correlate imaging and sialendoscopic findings to therapeutic response in patients with idiopathic chronic parotitis. Methods: We retrospectively reviewed 122 consecutive sialendoscopies performed in an academic medical center by two surgeons between 2008 and 2013. Forty-one (34%) and 54 (44%) patients were excluded on the basis of having parotid or submandibular sialolith, respectively. Nineteen cases were included in the study with idiopathic chronic parotitis. There was a median follow-up of 5 months. Results: Computed tomography (CT) imaging had a sensitivity and specificity of 80.0 and 71.4%, respectively, for predicting abnormal findings on sialendoscopy, while magnetic resonance imaging (MRI) had 100% accuracy in a small set of cases. In glands with noticeable pathology present on preoperative imaging or sialendoscopy, 11 out of 12 glands (92%) treated experienced symptomatic improvement, while 3 out of 7 glands (43%) without pathology on imaging or endoscopy experienced symptomatic improvement (p = 0.038). Conclusions: Sialendoscopy for the treatment of idiopathic chronic parotid disease can improve pain and swelling with a higher frequency of success in patients with abnormalities noted on endoscopy. CT and MRI have a moderate degree of accuracy in predicting which patients will benefit from therapeutic sialendoscopy.

1.
Königsberger R, Feyh J, Goetz A, Schilling V, Kastenbauer E: Endoscopic controlled laser lithotripsy in the treatment of sialolithiasis (in German). Laryngorhinootologie 1990;69:322-323.
2.
Raif J, Vardi M, Nahlieli O, Gannot I: An Er:YAG laser endoscopic fiber delivery system for lithotripsy of salivary stones. Lasers Surg Med 2006;38:580-587.
3.
Marchal F, Dulguerov P: Sialolithiasis management: the state of the art. Arch Otolaryngol Head Neck Surg 2003;129:951-956.
4.
Numminen J, Sillanpää S, Virtanen J, Sipilä M, Rautiainen M: Retrospective analysis of a combined endoscopic and transcutaneous technique for the management of parotid salivary gland stones. ORL J Otorhinolaryngol Relat Spec 2014;76:282-287.
5.
Zenk J, Koch M, Klintworth N, et al: Sialendoscopy in the diagnosis and treatment of sialolithiasis: a study of more than 1,000 patients. Otolaryngol Head Neck Surg 2012;147:858-863.
6.
Strychowsky JE, Sommer DD, Gupta MK, Cohen N, Nahlieli O: Sialendoscopy for the management of obstructive salivary gland disease: a systematic review and meta-analysis. Arch Otolaryngol Head Neck Surg 2012;138:541-547.
7.
Rahmati R, Gillespie MB, Eisele DW: Is sialendoscopy an effective treatment for obstructive salivary gland disease? Laryngoscope 2013;123:1828-1829.
8.
Reddy R, White DR, Gillespie MB: Obstructive parotitis secondary to an acute masseteric bend. ORL J Otorhinolaryngol Relat Spec 2012;74:12-15.
9.
Epker BN: Obstructive and inflammatory diseases of the major salivary glands. Oral Surg Oral Med Oral Pathol 1972;33:2-27.
10.
Shacham R, Droma EB, London D, Bar T, Nahlieli O: Long-term experience with endoscopic diagnosis and treatment of juvenile recurrent parotitis. J Oral Maxillofac Surg 2009;67:162-167.
11.
Nahlieli O, Baruchin AM: Long-term experience with endoscopic diagnosis and treatment of salivary gland inflammatory diseases. Laryngoscope 2000;110:988-993.
12.
Nahlieli O, Shacham R, Yoffe B, Eliav E: Diagnosis and treatment of strictures and kinks in salivary gland ducts. J Oral Maxillofac Surg 2001;59:484-492.
13.
Nahlieli O, Shacham R, Shlesinger M, Eliav E: Juvenile recurrent parotitis: a new method of diagnosis and treatment. Pediatrics 2004;114:9-12.
14.
Koch M, Zenk J, Bozzato A, Bumm K, Iro H: Sialoscopy in cases of unclear swelling of the major salivary glands. Otolaryngol Head Neck Surg 2005;133:863-868.
15.
Mandel SJ, Mandel L: Radioactive iodine and the salivary glands. Thyroid 2003;13:265-271.
16.
Nahlieli O, Nazarian Y: Sialadenitis following radioiodine therapy - a new diagnostic and treatment modality. Oral Dis 2006;12:476-479.
17.
Kim JW, Han GS, Lee HS, Lee DY, Kim YM: Sialoendoscopic treatment for radioiodine induced sialadenitis. Laryngoscope 2007;117:133-136.
18.
Bomeli SR, Schaitkin B, Carrau RL, Walvekar RR: Interventional sialendoscopy for treatment of radioiodine-induced sialadenitis. Laryngoscope 2009;119:864-867.
19.
Vashishta R, Gillespie MB: Salivary endoscopy for idiopathic chronic sialadenitis. Laryngoscope 2013;123:3016-3020.
20.
Bowen MA, Tauzin M, Kluka E: Diagnostic and interventional sialendoscopy: a preliminary experience. Laryngoscope 2011;121:299-303.
21.
Yu CQ, Yang C, Zheng ZY, Zhang Y Zhang L, Yu GY: Diagnosis and management of sialolithiasis with a semirigid endoscope. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009;108:9-14.
22.
Serbetci E, Sengor GA: Sialendoscopy: experience with the first 60 glands in Turkey and a literature review. Ann Otol Rhinol Laryngol 2010;119:155-164.
23.
Yu C, Yang C, Zheng L, Wu D: Endoscopic observation and strategic management of obstructive submandibular sialadenitis. J Oral Maxillofac Surg 2010;68:1770-1775.
24.
Ianovski I, Morton RP, Ahmad Z: Patient-perceived outcome after sialendoscopy using the Glasgow benefit inventory. Laryngoscope 2014;124:869-874.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.